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association was moderated by demographic (age, sex), psychological 
(depression, catastrophizing), or medication-related (opioid use) 
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Analyses, however, revealed that the magnitude of this association was 
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Abstract 
 
It is generally assumed that individuals exhibiting high pain inhibition also tend to exhibit 
low pain facilitation, but little research has examined this association in individuals with 
pain. The aims of this cross-sectional study were 1) to examine the association between 
measures of conditioned pain modulation (CPM) and temporal summation (TS) in 
individuals with chronic pain and 2) to examine whether this association was moderated 
by demographic (age, sex), psychological (depression, catastrophizing), or medication- 
related (opioid use) variables. individuals (n = 190) with back or neck pain completed 
questionnaires and underwent a series of quantitative sensory testing (QST) procedures 
assessing CPM and TS. Results indicated that individuals with higher levels of CPM 
showed lower levels of TS, r = -.20, p < .01. Analyses, however, revealed that the 
magnitude of this association was substantially weaker among opioid users (r = -.08, ns) 
than non-users (r = -.34, p < .01). None of the demographic or psychological variables 
included in our study influenced the association between CPM and TS. The magnitude 
of CPM was lower for opioid users than non-users, suggesting that opioid use might 
dampen the functioning of endogenous pain-inhibitory systems, and might contribute to 
a discordance between measures of pain inhibition and pain facilitation. 
Perspective 
Results of the present study indicated that greater endogenous pain-inhibitory capacity 
is associated with lower levels of pain facilitation. This association, however, was not 
significant among opioid users, suggesting that opioids might compromise the 
functioning and interrelationship between endogenous pain modulatory systems. 
Keywords 
Endogenous pain inhibition; pain facilitation; opioids; chronic pain 
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1.0. Introduction 
 
It is well known that nociceptive signals can be modulated by central pain 
inhibitory and facilitatory processes 1, 8, 82. These pain-modulatory processes operate at 
various levels of the central nervous system and are assumed to play a determining role 
in the manifestations of chronic pain and in shaping inter-individual variability in the 
trajectory of many persistent pain conditions 6, 25, 51, 83. Considerable studies have been 
conducted using quantitative sensory testing (QST) to assess pain inhibition and pain 
facilitation 9, 19, 71. For instance, conditioned pain modulation (CPM) and temporal 
summation (TS) paradigms have been used as indices of pain-inhibitory and pain- 
summation processes1, 4, 8. Evidence of impaired CPM and/or facilitated TS has been 
observed among individuals with a variety of chronic musculoskeletal, visceral, and 
neuropathic pain conditions (for reviews, see 6, 48, 71, 76). 
There has been growing interest in characterizing individuals with chronic pain 
based on their pain modulation profiles (PMPs) 4, 8, 56, 84, 86, as inter-individual variability 
in pain modulation has been shown to predict clinical outcomes such as development or 
worsening of pain after surgery 45, 55, 56. Studies also found that TS is a predictor of 
responses to cyclooxygenase-2 (COX-2) inhibitors 3 and that CPM is a predictor of 
responses to topical nonsteroidal anti-inflammatory drugs (NSAID) 27 as well as 
pregabalin treatment 13, 87. It has been argued that characterizing individuals with 
chronic pain based on their pain modulation profiles might provide valuable 
“mechanistic” information to clinicians in the context of pain assessment and 
individualized treatment selection 25, 56, 75, 84, 86. 
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One outstanding question in the literature on endogenous pain modulation is the 
manner in which pain-inhibitory processes (e.g., CPM) and pain-facilitatory processes 
(e.g., TS) inter-relate. For instance, some have hypothesized a concordance between 
these measures84, 86, as individuals with low CPM would be expected to exhibit high TS, 
and vice versa. Psychophysical studies suggest that descending pain-inhibitory systems 
can modulate pain-facilitatory processes such as temporal summation 33, 64, 67. To date, 
however, it remains unclear whether individual differences in CPM and TS are 
associated, and very little research has been conducted on the nature of the association 
between these measures of pain modulation among individuals with chronic pain. 
One of the few studies that has grouped together clusters of individuals with pain 
on the basis of both pain inhibition and pain facilitation reported an interactive effect of 
these measures, with those who had a combination of poor CPM and elevated TS 
showing the worst pain after joint replacement surgery 56. However, that study was not 
designed to evaluate the basal inter-correlation between CPM and TS, and it is 
unknown to what extent these factors tend to cluster within individual patients. 
Moreover, previous studies have shown that endogenous pain inhibition and pain 
summation may be influenced by a number of demographic variables, such as age and 
sex 37, 48, 76, and by psychological variables such as catastrophizing 34, 38, 57, 80 and 
negative affect 21, 39, 61, which suggests that any CPM-TS relationships could be 
influenced by such variables. Furthermore, a number of studies have also shown that 
medications, such as opioids, may also affect endogenous pain-modulatory processes 2, 
60, 73. Thus, there is reason to believe that some of these factors could contribute to 
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enhancing or decreasing the strength of the association between measures of pain 
inhibition and pain summation among individuals with pain. 
The aims of this study were 1) to examine the association between measures of 
CPM and TS in a large cohort of individuals with chronic pain, 2) to examine the 
potential moderating role of demographic and psychological factors in the association 
between CPM and TS, and 3) to investigate the role of opioid use in the association 
between CPM and TS. 
2.0. Methods 
 
2.1. Participants 
 
A sample of 190 individuals with chronic back or neck pain was included in this 
cross-sectional study. Participants were part of broader study project examining the 
psychophysical correlates of long-term opioid use. Although some data from  the 
broader parent study were previously published 35, this is our first report specifically 
examining the association between measures of CPM and TS. Participants in the parent 
study were recruited via treating physicians at Brigham and Women’s Hospital (BWH) 
and local posting of print advertisements around the BWH Pain Management Center. 
Participants met the following inclusion criteria: (1) chronic back or neck pain, (2) had 
been experiencing pain for at least 6 months (3) able to speak, read, and write in 
English. They were excluded if (4) they had cancer, bone disease, heart disease, or a 
neurological disease, or (5) cognitive limitations that precluded providing self-report 
data. Individuals with (6) any active addiction problem (i.e., substance use disorder) 
were not included in the present study given the current clinical practice guidelines and 
principles at the BWH Pain Center regarding the management of patients with 
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substance use disorder (SUD). Patients with active SUD are generally referred to a 
local addiction treatment facility before undergoing pain treatment at the Pain Center 
and before being eligible for study participation. For the purposes of the present report, 
(7) individuals taking non-opioid adjuvant medications in addition to prescription opioids, 
such as antidepressants, anticonvulsants or sedatives were excluded from the study 
sample given the potential influence of these medications on endogenous pain 
modulatory systems 5, 7, 36, 79, 89. 
2.2. Procedure & measures 
 
The Human Subjects Committee of BWH approved all study procedures. 
Interested participants underwent a telephone-based screening before coming in for the 
study visit. Upon arrival at the laboratory, participants underwent the process of 
providing informed consent, signed a consent form, and were asked to complete a 
demographic questionnaire, which included information about age, gender, and 
ethnicity. Participants also provided information on pain diagnosis and pain duration. 
They were then asked to report all the medications they were currently taking. Reports 
of medication were verified by a research assistant after the study session using the 
electronic medical record system, and published tables 24 were used to convert opioid 
doses into morphine equivalent daily doses (MEDD). In addition to providing this 
information, participants were asked to complete self-report questionnaires assessing 
pain and psychological variables, and then underwent a series of standardized 
quantitative sensory testing procedures (see below). 
2.2.1. Clinical pain severity 
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The Brief Pain Inventory (BPI 74) was used as a measure of chronic pain severity. 
On the BPI, participants were asked to rate their average level of pain intensity (i.e., 
over the past 24 hours) on a numeric rating scale (NRS) that ranged from 0 (no pain)  to 
10 (extreme pain). Participants were also asked to rate the degree to which pain 
interferes with various domains of functioning on a NRS that ranged from 0 (does not 
interfere) to 10 (completely interferes). The BPI has been shown to be a reliable and 
valid measure of pain severity and pain interference among individuals with chronic pain 
46, 47, 74. 
 
2.2.2. Pain catastrophizing 
 
The Pain Catastrophizing Scale (PCS 68) was used as a measure of catastrophic 
thinking about pain. The PCS contains 13 items describing different thoughts and 
feelings that individuals may experience when they are in pain. Participants were asked 
to reflect on past painful experiences and to indicate the degree to which they 
experienced each of 13 thoughts or feelings when experiencing pain, on a 5-point scale 
ranging from 0 (not at all) to 4 (all the time). Numerous studies have supported the 
reliability and the validity of the PCS as a measure of pain-related catastrophic thinking 
among individuals with chronic pain 26, 54, 70. 
2.2.3. Depressive symptoms 
 
The Beck Depression Inventory (BDI-II 10) was used as a measure of depressive 
symptomatology. The BDI-II consists of 21 items describing various symptoms of 
depression, and participants choose statements that describe how they have been 
feeling over the past two weeks. Responses are summed to yield an overall index of 
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depressive symptoms. The BDI has been shown to be a reliable and valid index of 
depressive symptoms among individuals with chronic pain 58, 69, 78. 
2.2.4. Quantitative sensory testing (QST) 
 
During the QST session, participants were seated comfortably in a reclining chair 
while they underwent a standardized battery of psychophysical pain testing procedures. 
A trained research assistant sat with participants throughout the QST session. The QST 
session involved assessment of warmth and cool thresholds, heat pain thresholds 
(HPTh), cold pain thresholds (CPTh), and heat pain tolerance (HPTo), all tested on the 
ventral forearm. Pressure pain thresholds (PPT) at the joint of the thumb were also 
assessed. For purposes of the present study, only the mechanical temporal summation 
of pain (TS) and conditioned pain modulation (CPM) procedures are described below. 
2.2.4.1. Temporal summation 
 
Participants underwent an assessment of mechanical temporal summation using 
a set of 7 custom-made weighted pinprick stimulators developed by the German 
research Network on Neuropathic Pain 62, 63. These punctuate mechanical probes have 
a flat contact area of .2 mm in diameter, and exert forces between 8 and 512 mN. 
Punctate stimuli were delivered to the skin on the dorsum of the middle finger of the 
right hand. Participants were first familiarized with the procedure by undergoing a 
practice trial (on the palm of their hand) during which we determined the lowest force 
stimulator that produced a painful sensation (128 or 256 mN for most participants). This 
force was then used to apply a train of 10 stimuli at the rate of 1 per second for the 
assessment of temporal summation. Participants rated the painfulness of the first, fifth, 
and tenth stimulus on a 0 to 100 verbal pain intensity scale. An index of temporal 
9 
Opioids and pain modulation 
 
 
 
summation was derived by subtracting participants’ 1st pinprick pain rating from the last 
(10th) pinprick pain rating. Higher (positive) scores represented higher levels of temporal 
summation (i.e., pain facilitation) 32, 35. 
2.2.4.2. Conditioned pain modulation 
 
In order to assess CPM, baseline pressure pain thresholds (PPTs) were first 
assessed using a handheld digital pressure algometer (Somedic, Hörby, Sweden) on 
the right upper trapezius, approximately 2 cm from the acromioclavicular joint. Given 
that participants had previously been familiarized with pressure pain threshold (PPT) 
assessment (assessed at the thumb) earlier during the QST session, CPM testing did 
not involve any practice trial. During baseline assessment of PPT at the trapezius, 
mechanical force was applied using a 0.5-cm2 probe covered with polypropylene 
pressure-transducing material. Pressure was increased at a steady rate of 30 kPa/s  
until the subject indicated that the pressure was “first perceived as painful.” Immediately 
following the assessment of PPT, participants underwent a cold pressor test (CPT). 
During the CPT, participants immersed their contralateral (left) hand up to the wrist in a 
circulating cold water bath maintained at 4°C, a water temperature used as conditioning 
stimulus in many previous CPM studies 12, 38, 64. Twenty seconds following hand 
immersion, PPT was reassessed on the right trapezius (i.e., the same site as baseline 
assessment). Participants were asked to remove their arm from the water 30 seconds 
after arm immersion. A second CPM trial was conducted two minutes after the end of 
the first CPM trial. The use of a 2-minute rest period between CPM trials is consistent 
with procedures that have been used in several previous CPM studies using the cold 
pressor test as the conditioning stimulus 30, 33, 38. Assessing CPM twice is also 
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consistent with recommendations on CPM testing. 85 For each of the CPM trials, a CPM 
index was derived by calculating the percent ratio of PPT during CPT to PPT prior to 
CPT. Scores from these two CPM trials were averaged, and higher CPM scores 
represented greater pain-inhibitory capacity.28, 31, 65, 85 
3.0. Data Reduction and Analysis 
 
All data were analyzed using IBM-SPSS v.21 (Chicago, IL, USA). The alpha level 
for significance was set to p < .05 for all analyses, and p-values above .05 are labeled in 
the Results section as NS (non-significant). Descriptive data for continuous variables 
were presented as means and standard deviations, and data for categorical variables 
were presented as percentages. Data for one of the CPM trials were missing for 7% of 
participants (i.e., 13/190). For these participants, data from the first CPM trial were used 
for the computation of the final CPM index. 
Prior to conducting the primary study analyses, the potential confounding 
influence of ethnicity, clinical pain intensity, pain interference, and pain duration on CPM 
and TS was examined. Variables associated either with CPM or TS were retained as 
covariates in subsequent analyses. 
A Pearson correlation was first computed to examine the association between 
CPM and TS. Pearson correlations were then computed to examine the association 
between psychological factors (i.e., catastrophizing, depressive symptoms) and 
endogenous pain modulation measures (i.e., CPM, TS), and independent samples t- 
tests were used to examine whether CPM and TS scores varied as a function of 
participant sex (i.e., men/women) and opioid status (i.e., opioid users/non-users). 
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In order to examine the potential moderating role of age, sex, opioid status, and 
psychological factors in the association between CPM and TS, five distinct moderation 
analyses were conducted using the PROCESS macro developed by Hayes et al. 43 For 
each of these moderation analyses, the TS index was used as the dependent variable, 
and two-way interaction terms between the CPM index and potential moderators (i.e., 
age, sex, opioid status, catastrophizing, depressive symptoms) were specified after 
inclusion of appropriate main effects. Any significant two-way interaction effect would 
suggest that the association between CPM and TS is moderated by participant age, 
sex, opioid status, catastrophizing, or depressive symptoms. Bias-corrected 95% 
confidence intervals (CI) were generated based on 5,000 bootstrap resamples, and CIs 
were presented along with p-values to interpret the significance of 
interaction/moderation effects. As recommended, moderation effects were considered 
significant in the case zero was not included within the CIs. Bootstrapping has been 
widely recommended because it improves power, but it was estimated that our sample 
size would be sufficient in order to detect medium-to-large effects using bootstrapping 
with two independent variables (IVs), an alpha set to .05, and a power of .80.43 
4.0. Results 
 
4.1. Descriptive statistics 
 
Descriptive statistics are presented in Table 1. In the present sample, 64 % (n = 
 
122) of participants were taking opioids (average daily opioid dose = 101.0 morphine 
equivalents; SD = 114.8). 
Prior to conducting primary analyses, the potential confounding influence of 
ethnicity, clinical pain intensity, pain interference, and pain duration on primary study 
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variables (i.e., CPM, TS) was examined. For opioid users, the influence of daily opioid 
dose on CPM and TS was also examined. None of these variables were significantly 
associated with either CPM or TS (see Table 2). Opioid users and non-users differed 
significantly on measures of clinical pain intensity (t (176) = -7.3, p < .01) and pain 
interference (t (154) = -8.4, p < .01), but not in pain duration. 
4.2. Association between psychological factors and endogenous pain modulation 
 
Table 2 also shows the correlations between psychological factors and 
endogenous pain modulation measures. Correlational analyses revealed a marginally 
significant negative association between catastrophizing and CPM (r = -.14, p = .05), 
indicating that higher levels of catastrophizing were associated with lower CPM. A 
significant positive correlation was found between catastrophizing and TS (r = .15, p < 
.05). Depressive symptoms were not significantly associated with either CPM or TS. 
 
Independent samples t-tests were used to examine whether CPM and TS scores 
varied as a function of participant sex (i.e., men/women) and opioid status (i.e., opioid 
users/non-users). Results indicated that there were no significant sex differences either 
in CPM (t (188) = 1.8, NS) or TS (t (188) = -.62, NS). Results of t-tests, however, 
indicated a marginally significant difference in CPM as a function of opioid status, with 
lower CPM scores for opioid users than non-users, t (188) = 2.1, p < .05. Opioid users 
and non-users did not differ significantly on the TS index, t (188) = -0.10, NS (see 
Figures 1 and 2). 
4.3. Association between CPM and TS 
 
A Pearson correlation was computed to examine the association between CPM 
and TS. Results revealed a significant negative correlation between CPM and TS 
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scores (r = -.20, p < .01), indicating that higher levels of CPM were associated with 
lower levels of temporal summation. 
4.4. Moderators of the association between CPM and TS 
 
As noted previously, five distinct bootstrapped moderation analyses were 
conducted to examine whether age, sex, opioid status, catastrophizing, or depressive 
symptoms moderated the association between CPM and TS. Results from these 
analyses indicated no significant 2-way interactions between CPM and participant age 
(B = .001, SE = .004, NS), sex (B = .053, SE = .099, NS), catastrophizing (B = -.006, SE 
= .004, NS), or depressive symptoms (B = -.001, SE = .006, NS). The two-way 
interaction effect between CPM and opioid status, however, was significant (B = .194, 
SE = .091, p < .05; LLCI = .014; ULCI = .375), indicating that the association between 
CPM and TS was moderated by participants’ opioid status. Simple slope analyses were 
subsequently conducted in order to probe the interaction of CPM and opioid status on 
TS. As can be seen from Figure 3, the association between CPM and TS varied as a 
function of participants’ opioid status (i.e., opioid users vs non-users). Results revealed 
a significant association between CPM and TS for non-users (r = -.34, p < .01), but not 
for opioid users (r = -.08, NS). 
5.0. Discussion 
 
Results of this study indicated that greater endogenous pain-inhibitory capacity is 
associated with lower levels of pain summation. Further, a moderation analysis revealed 
that the magnitude of this association differed significantly as a function of participants’ 
opioid status, with opioid use appearing to reduce the magnitude of the inverse 
relationship between CPM and TS. None of the demographic or psychologic variables 
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included in the present study were found to moderate the association between CPM 
and TS. 
The association that was found between CPM and TS is generally consistent  
with heuristic models of endogenous pain modulation that implicitly assume a certain 
degree of concordance between measures of pain inhibition and facilitation 4, 20, 27, 66, 84, 
86. For instance,  individuals  exhibiting either high  pain inhibition (high  CPM), low  pain 
 
summation (low TS), or both, have been collectively described as having an 
“antinociceptive” pain modulation phenotype, as opposed to a pro-nociceptive 
phenotype characterized by high TS and low CPM 40, 86. It is also noteworthy that 
individuals with chronic pain conditions characterized by “dysfunctional” pain modulation 
tend to show both decrements in CPM and elevations in TS relative to controls 1, 8, 22, 23, 
66. On the basis of this model, one would expect an inverse association between indices 
 
of endogenous pain inhibition and endogenous pain facilitation, which is what we 
observed in the present study. In addition, two recent studies found that roughly 30 % of 
individuals with “normal” or “higher-than-average” CPM levels were characterized by 
low levels of TS 56, 75, which is also consistent with our results. 
Interestingly, the present study found an association between measures of CPM 
and TS selectively among individuals who are not using opioids. While a number of 
factors might account for the altered association between CPM and TS among opioid 
users, our data suggest that this might be due at least in part to the potentially disruptive 
effects of exogenous opioids on individuals’ endogenous pain-inhibitory capacity. 
Consistent with previous work 29, 59, we found that the magnitude of CPM was lower for 
opioid users than non-users, suggesting that opioid use might dampen the functioning 
15 
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of endogenous pain-inhibitory systems. Interestingly, several recent experimental 
studies have found that acute opioid administration may enhance endogenous pain 
inhibition 2, 53, and other reports of short-term administration have suggested minimal 
effects 73. Collectively, these findings may suggest that the impact of opioid use on 
indices of pain inhibition shows a biphasic time course, with acute potentiation of CPM 
followed by long-term decrements of CPM. There is now compelling evidence both from 
preclinical 15, 50 and clinical 77, 88 studies that opioid use, over time, may progressively 
lead to enduring neuroplastic changes at various levels of the central nervous system 
(CNS), including within neural pathways known to be involved in endogenous pain 
inhibition. To the extent that endogenous pain-inhibitory systems exert a modulatory 
influence upon pain summation 6, 25, 41, 81, opioid-induced disruption of pain-inhibitory 
function might compromise the expected association between pain inhibition and pain 
facilitation, as observed among opioid users included in the present study. Although 
speculative, a disruption of pain-inhibitory function as a result of repeated opioid use 
might contribute to enhanced descending facilitatory activity and, in turn, to opioid- 
induced hyperalgesia (OIH), a phenomenon observed both experimentally and clinically 
16, 17, 49, 72. The observational nature of our study design prevents from concluding that 
 
opioid use caused hyperalgesic responses (i.e., opioid-induced hyperalgesia). However, 
the significantly lower pain-inhibitory (i.e., CPM) function and heightened clinical pain 
intensity levels observed among opioid users compared to non-users provide partial 
support for this notion. Previous studies among individuals with chronic pain have also 
observed disruptions in CPM 28, 60, 90 and heightened clinical pain intensity levels 17, 18 
among long-term opioid users. However, given that these studies were also based on 
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observational study designs, research will be needed to determine whether a disruption 
of the association between pain-inhibitory and pain-facilitatory mechanisms may 
contribute to the development of opioid-induced hyperalgesia among individuals who 
initiate opioid therapy. 
The findings of the present study have not only implications for conceptual 
models of endogenous pain modulation, but also for the assessment of pain-modulatory 
profiles in treatment settings. For instance, the modest overlap (i.e., concordance) 
between measures CPM and TS suggests considerable inter-individual heterogeneity 
within each of the pain modulation profiles. Consequently, in clinic settings, these two 
measures should not be used interchangeably to derive inferences about individuals’ 
pain modulation. The predictive consideration of both CPM and TS paradigms is likely  
to yield a more reliable and comprehensive assessment of pain modulation profiles 55. 
Our findings also suggest that a certain “discordance” between measures of 
endogenous pain inhibition (i.e., CPM) and pain facilitation (i.e., TS) might be more 
particularly pronounced among specific subgroups of individuals with chronic pain, such 
as those using opioid medication. Given that the coupling of high pain inhibition and low 
pain facilitation is viewed as an optimal pain modulation profile (i.e., an “antinociceptive” 
PMP) with the potential for buffering against negative pain-related outcomes 25, 84, 86, the 
putative deleterious impact of opioids on individuals’ pain modulation profiles should be 
considered over the course of treatment selection, either in the context of perioperative 
or chronic pain management. Future research should also examine whether the 
association between pain inhibition and pain facilitation is enhanced when individuals 
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are discontinuing or tapering off opioid medication, as well as the time course of these 
putative shifts in pain modulation produced by changes in opioid treatments. 
A number of limitations must be considered when interpreting the present 
findings. First, this study report is based on a convenience sample, which limited our 
explanatory reach in accounting for some of the findings that were reported. Second, 
due to the cross-sectional nature of the study design, individuals’ levels of CPM and TS 
were assessed only at a single point in time. While these two measures have been 
found to be relatively stable over time 11, 14, 42, 44, 52, future studies involving repeated 
assessment of CPM and TS would allow one to derive more reliable inferences about 
the magnitude of the association between these two forms of endogenous pain 
modulation. Third, participants in the present study were taking relatively high doses of 
opioids considering recent changes in opioid prescribing guidelines 24. Daily opioid 
doses were neither associated with CPM nor TS, but further studies will need to 
determine whether our findings can be generalized to patients taking lower opioid 
doses. It will also be important to further evaluate the influence of opioid dose and 
opioid use duration to the functioning of endogenous pain modulation systems. Fourth, 
individuals taking non-opioid analgesic medications were not included in the analyses. 
While this may be seen as a methodological strength, as it permitted us to rule out the 
influence of non-opioid medication on endogenous pain modulation, this places limits on 
the generalizability of our findings. Fifth, we did not measure potentially important 
variables, such as the duration of opioid therapy or the recency of opioid use in relation 
to QST. Future studies should control for inter-individual differences in these variables 
as they might influence measures of pain modulation. Finally, CPM was derived only on 
18 
Opioids and pain modulation 
 
 
 
the basis of the cold pressor test and pressure pain stimuli. Replication of our findings 
using other methods or CPM paradigms (i.e., using other conditioning and/or test 
stimuli) 44 is warranted before drawing more firm conclusions regarding the association 
between CPM and TS. 
Conclusion 
 
Findings from the present study provide new insights into the association 
between endogenous pain-inhibitory and pain summation systems, showing an inverse 
relationship between CPM and TS among individuals with chronic pain. That is, those 
exhibiting higher levels of CPM showed lower levels of TS. While the coupling of high 
pain inhibition and low pain facilitation is viewed as an optimal endogenous pain 
modulation profile that may buffer against negative pain-related outcomes 25, 84, the 
present findings suggest that opioid use might disrupt endogenous pain-inhibitory 
function and, in turn, the association between endogenous pain-inhibitory (i.e., CPM) 
and pain-facilitatory (TS) systems. Given that an impaired association between pain- 
inhibitory and pain-facilitatory systems is expected to increase individuals’ vulnerability 
to poor pain-related outcomes 25, 56, 84, further research will be needed to identify the 
factors that may impair the interrelationship between these endogenous pain 
modulatory systems. Research will also be needed to determine whether a disruption of 
the association between pain-inhibitory and pain-facilitatory mechanisms may contribute 
to long-term sensitization and hyperalgesic responses (i.e., opioid-induced 
hyperalgesia) among opioid users. Research in this area would provide additional 
insights into the potentially deleterious impact of opioids on endogenous pain 
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modulation systems, and would have implications for the management of individuals 
with pain conditions. 
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Table 1 
 
 
 
 
 
 
 
Table 1 
Sample characteristics and descriptive data for main study variables 
Variables 
Age 49.5 ± 10.9 
Sex (% women) 43 % 
Ethnicity (% white) 65 % 
Pain duration (years) 10.8 ± 8.6 
Pain location 
Back or neck pain 100 % 
Radiating pain; lower 32 % 
Radiating pain; upper 47 % 
Pain intensity (BPI) 5.0 ± 2.4 
Pain interference (BPI) 4.3 ± 2.9 
Catastrophizing (PCS) 20.0 ± 12.1 
Depressive symptoms (BDI) 11.6 ± 8.3 
 
Note. ± represents standard deviations; BPI: Brief Pain Inventory; PCS: 
Pain Catastrophizing Scale; BDI: Beck Depression Inventory; Lower refers 
to legs and feet. Upper refers to shoulders and arms 
Table 2 
 
 
 
 
 
 
 
Table 2 
Correlations among study measures 
 
 
1 2 3 4 5 6 7 8 9 
 
1. Age 
 
- 
 
-.06 
 
.11 
 
-.37** 
 
-.27** 
 
-.31** 
 
-.18** 
 
.13 
 
.02 
2. Opioid dose†  - -.12 .08 -.05 -.10 -.24 .03 -.13 
3. Pain duration   - .29* .19 .18 .13 -.24 .18 
4. Pain intensity (BPI)    - .71** .51** .32** -.10 .07 
5. Pain interference (BPI)     - .46** .39** -.04 .00 
6. Catastrophizing (PCS)      - .41** -.14 .15* 
7. Depressive symptoms (BDI)       - .01 .00 
8. Conditioned pain modulation        - -.20** 
9. Temporal summation         - 
** Correlation is significant at the .01 level. * Correlation is significant at the .05 level. † Only among 
opioid users; BPI: Brief Pain Inventory; PCS: Pain Catastrophizing Scale; BDI: Beck Depression 
Inventory 
Table 3 
 
 
 
 
 
 
 
Table 3 
Pressure pain thresholds and cold water pain during the conditioned pain modulation (CPM) test 
 
 
 Opioid users Non-users p 
CPM: Trial 1    
PPTh-Pre 373.5 (195.9) 326.1 (120.2) < .05 
Cold water pain 52.2 (24.9) 64.35 (26.5) ns 
PPTh-Post 448.3 (234.9) 422.8 (160.5) ns 
CPM: Trial 2 
   
PPTh-Pre 449.7 (223.1) 331.9 (120.9) < .05 
Cold water pain 58.2 (26.3) 68.7 (25.1) ns 
PPTh-Post 517.3 (260.7) 388.1 (137.9) < .05 
 
 
Note: PPTh-Pre: pressure pain thresholds before the water bath; Cold water pain: pain ratings 
during the water bath; PPTh-Pre: Pressure pain thresholds 20 seconds after cold pain (i.e., 
water bath) onset; Numbers in parentheses are standard deviations. 
Table 4 
 
 
 
 
 
 
 
Table 4 
Pinprick pain ratings during the temporal summation of pain (TSP) test 
 
 
 Opioid users Non-users p 
TSP 
1st stimulus 
 
 
13.3 (14.3) 
 
 
16.3 (16.8) 
 
 
ns 
10th stimulus 27.2 (23.9) 29.8 (29.4) ns 
 
 
Note: 1st stimulus refers to the pain rating (0-100) provided immediately after the first stimulus; 
10th stimulus: Refers to the pain rating (0-100) provided immediately after the tenth stimulus. 
*Manuscript (revised, clean) 
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Abstract 
 
It is generally assumed that individuals exhibiting high pain inhibition also tend to exhibit 
low pain facilitation, but little research has examined this association in individuals with 
pain. The aims of this cross-sectional study were 1) to examine the association between 
measures of conditioned pain modulation (CPM) and temporal summation (TS) in 
individuals with chronic pain and 2) to examine whether this association was moderated 
by demographic (age, sex), psychological (depression, catastrophizing), or medication- 
related (opioid use) variables. individuals (n = 190) with back or neck pain completed 
questionnaires and underwent a series of quantitative sensory testing (QST) procedures 
assessing CPM and TS. Results indicated that individuals with higher levels of CPM 
showed lower levels of TS, r = -.20, p < .01. Analyses, however, revealed that the 
magnitude of this association was substantially weaker among opioid users (r = -.08, ns) 
than non-users (r = -.34, p < .01). None of the demographic or psychological variables 
included in our study influenced the association between CPM and TS. The magnitude 
of CPM was lower for opioid users than non-users, suggesting that opioid use might 
dampen the functioning of endogenous pain-inhibitory systems, and might contribute to 
a discordance between measures of pain inhibition and pain facilitation. 
Perspective 
Results of the present study indicated that greater endogenous pain-inhibitory capacity 
is associated with lower levels of pain facilitation. This association, however, was not 
significant among opioid users, suggesting that opioids might compromise the 
functioning and interrelationship between endogenous pain modulatory systems. 
Keywords 
Endogenous pain inhibition; pain facilitation; opioids; chronic pain 
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1.0. Introduction 
 
It is well known that nociceptive signals can be modulated by central pain 
inhibitory and facilitatory processes 1, 8, 82. These pain-modulatory processes operate at 
various levels of the central nervous system and are assumed to play a determining role 
in the manifestations of chronic pain and in shaping inter-individual variability in the 
trajectory of many persistent pain conditions 6, 25, 51, 83. Considerable studies have been 
conducted using quantitative sensory testing (QST) to assess pain inhibition and pain 
facilitation 9, 19, 71. For instance, conditioned pain modulation (CPM) and temporal 
summation (TS) paradigms have been used as indices of pain-inhibitory and pain- 
summation processes1, 4, 8. Evidence of impaired CPM and/or facilitated TS has been 
observed among individuals with a variety of chronic musculoskeletal, visceral, and 
neuropathic pain conditions (for reviews, see 6, 48, 71, 76). 
There has been growing interest in characterizing individuals with chronic pain 
based on their pain modulation profiles (PMPs) 4, 8, 56, 84, 86, as inter-individual variability 
in pain modulation has been shown to predict clinical outcomes such as development or 
worsening of pain after surgery 45, 55, 56. Studies also found that TS is a predictor of 
responses to cyclooxygenase-2 (COX-2) inhibitors 3 and that CPM is a predictor of 
responses to topical nonsteroidal anti-inflammatory drugs (NSAID) 27 as well as 
pregabalin treatment 13, 87. It has been argued that characterizing individuals with 
chronic pain based on their pain modulation profiles might provide valuable 
“mechanistic” information to clinicians in the context of pain assessment and 
individualized treatment selection 25, 56, 75, 84, 86. 
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One outstanding question in the literature on endogenous pain modulation is the 
manner in which pain-inhibitory processes (e.g., CPM) and pain-facilitatory processes 
(e.g., TS) inter-relate. For instance, some have hypothesized a concordance between 
these measures84, 86, as individuals with low CPM would be expected to exhibit high TS, 
and vice versa. Psychophysical studies suggest that descending pain-inhibitory systems 
can modulate pain-facilitatory processes such as temporal summation 33, 64, 67. To date, 
however, it remains unclear whether individual differences in CPM and TS are 
associated, and very little research has been conducted on the nature of the association 
between these measures of pain modulation among individuals with chronic pain. 
One of the few studies that has grouped together clusters of individuals with pain 
on the basis of both pain inhibition and pain facilitation reported an interactive effect of 
these measures, with those who had a combination of poor CPM and elevated TS 
showing the worst pain after joint replacement surgery 56. However, that study was not 
designed to evaluate the basal inter-correlation between CPM and TS, and it is 
unknown to what extent these factors tend to cluster within individual patients. 
Moreover, previous studies have shown that endogenous pain inhibition and pain 
summation may be influenced by a number of demographic variables, such as age and 
sex 37, 48, 76, and by psychological variables such as catastrophizing 34, 38, 57, 80 and 
negative affect 21, 39, 61, which suggests that any CPM-TS relationships could be 
influenced by such variables. Furthermore, a number of studies have also shown that 
medications, such as opioids, may also affect endogenous pain-modulatory processes 2, 
60, 73. Thus, there is reason to believe that some of these factors could contribute to 
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enhancing or decreasing the strength of the association between measures of pain 
inhibition and pain summation among individuals with pain. 
The aims of this study were 1) to examine the association between measures of 
CPM and TS in a large cohort of individuals with chronic pain, 2) to examine the 
potential moderating role of demographic and psychological factors in the association 
between CPM and TS, and 3) to investigate the role of opioid use in the association 
between CPM and TS. 
2.0. Methods 
 
2.1. Participants 
 
A sample of 190 individuals with chronic back or neck pain was included in this 
cross-sectional study. Participants were part of broader study project examining the 
psychophysical correlates of long-term opioid use. Although some data from  the 
broader parent study were previously published 35, this is our first report specifically 
examining the association between measures of CPM and TS. Participants in the parent 
study were recruited via treating physicians at Brigham and Women’s Hospital (BWH) 
and local posting of print advertisements around the BWH Pain Management Center. 
Participants met the following inclusion criteria: (1) chronic back or neck pain, (2) had 
been experiencing pain for at least 6 months (3) able to speak, read, and write in 
English. They were excluded if (4) they had cancer, bone disease, heart disease, or a 
neurological disease, or (5) cognitive limitations that precluded providing self-report 
data. Individuals with (6) any active addiction problem (i.e., substance use disorder) 
were not included in the present study given the current clinical practice guidelines and 
principles at the BWH Pain Center regarding the management of patients with 
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substance use disorder (SUD). Patients with active SUD are generally referred to a 
local addiction treatment facility before undergoing pain treatment at the Pain Center 
and before being eligible for study participation. For the purposes of the present report, 
(7) individuals taking non-opioid adjuvant medications in addition to prescription opioids, 
such as antidepressants, anticonvulsants or sedatives were excluded from the study 
sample given the potential influence of these medications on endogenous pain 
modulatory systems 5, 7, 36, 79, 89. 
2.2. Procedure & measures 
 
The Human Subjects Committee of BWH approved all study procedures. 
Interested participants underwent a telephone-based screening before coming in for the 
study visit. Upon arrival at the laboratory, participants underwent the process of 
providing informed consent, signed a consent form, and were asked to complete a 
demographic questionnaire, which included information about age, gender, and 
ethnicity. Participants also provided information on pain diagnosis and pain duration. 
They were then asked to report all the medications they were currently taking. Reports 
of medication were verified by a research assistant after the study session using the 
electronic medical record system, and published tables 24 were used to convert opioid 
doses into morphine equivalent daily doses (MEDD). In addition to providing this 
information, participants were asked to complete self-report questionnaires assessing 
pain and psychological variables, and then underwent a series of standardized 
quantitative sensory testing procedures (see below). 
2.2.1. Clinical pain severity 
7 
Opioids and pain modulation 
 
 
 
The Brief Pain Inventory (BPI 74) was used as a measure of chronic pain severity. 
On the BPI, participants were asked to rate their average level of pain intensity (i.e., 
over the past 24 hours) on a numeric rating scale (NRS) that ranged from 0 (no pain)  to 
10 (extreme pain). Participants were also asked to rate the degree to which pain 
interferes with various domains of functioning on a NRS that ranged from 0 (does not 
interfere) to 10 (completely interferes). The BPI has been shown to be a reliable and 
valid measure of pain severity and pain interference among individuals with chronic pain 
46, 47, 74. 
 
2.2.2. Pain catastrophizing 
 
The Pain Catastrophizing Scale (PCS 68) was used as a measure of catastrophic 
thinking about pain. The PCS contains 13 items describing different thoughts and 
feelings that individuals may experience when they are in pain. Participants were asked 
to reflect on past painful experiences and to indicate the degree to which they 
experienced each of 13 thoughts or feelings when experiencing pain, on a 5-point scale 
ranging from 0 (not at all) to 4 (all the time). Numerous studies have supported the 
reliability and the validity of the PCS as a measure of pain-related catastrophic thinking 
among individuals with chronic pain 26, 54, 70. 
2.2.3. Depressive symptoms 
 
The Beck Depression Inventory (BDI-II 10) was used as a measure of depressive 
symptomatology. The BDI-II consists of 21 items describing various symptoms of 
depression, and participants choose statements that describe how they have been 
feeling over the past two weeks. Responses are summed to yield an overall index of 
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depressive symptoms. The BDI has been shown to be a reliable and valid index of 
depressive symptoms among individuals with chronic pain 58, 69, 78. 
2.2.4. Quantitative sensory testing (QST) 
 
During the QST session, participants were seated comfortably in a reclining chair 
while they underwent a standardized battery of psychophysical pain testing procedures. 
A trained research assistant sat with participants throughout the QST session. The QST 
session involved assessment of warmth and cool thresholds, heat pain thresholds 
(HPTh), cold pain thresholds (CPTh), and heat pain tolerance (HPTo), all tested on the 
ventral forearm. Pressure pain thresholds (PPT) at the joint of the thumb were also 
assessed. For purposes of the present study, only the mechanical temporal summation 
of pain (TS) and conditioned pain modulation (CPM) procedures are described below. 
2.2.4.1. Temporal summation 
 
Participants underwent an assessment of mechanical temporal summation using 
a set of 7 custom-made weighted pinprick stimulators developed by the German 
research Network on Neuropathic Pain 62, 63. These punctuate mechanical probes have 
a flat contact area of .2 mm in diameter, and exert forces between 8 and 512 mN. 
Punctate stimuli were delivered to the skin on the dorsum of the middle finger of the 
right hand. Participants were first familiarized with the procedure by undergoing a 
practice trial (on the palm of their hand) during which we determined the lowest force 
stimulator that produced a painful sensation (128 or 256 mN for most participants). This 
force was then used to apply a train of 10 stimuli at the rate of 1 per second for the 
assessment of temporal summation. Participants rated the painfulness of the first, fifth, 
and tenth stimulus on a 0 to 100 verbal pain intensity scale. An index of temporal 
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summation was derived by subtracting participants’ 1st pinprick pain rating from the last 
(10th) pinprick pain rating. Higher (positive) scores represented higher levels of temporal 
summation (i.e., pain facilitation) 32, 35. 
2.2.4.2. Conditioned pain modulation 
 
In order to assess CPM, baseline pressure pain thresholds (PPTs) were first 
assessed using a handheld digital pressure algometer (Somedic, Hörby, Sweden) on 
the right upper trapezius, approximately 2 cm from the acromioclavicular joint. Given 
that participants had previously been familiarized with pressure pain threshold (PPT) 
assessment (assessed at the thumb) earlier during the QST session, CPM testing did 
not involve any practice trial. During baseline assessment of PPT at the trapezius, 
mechanical force was applied using a 0.5-cm2 probe covered with polypropylene 
pressure-transducing material. Pressure was increased at a steady rate of 30 kPa/s  
until the subject indicated that the pressure was “first perceived as painful.” Immediately 
following the assessment of PPT, participants underwent a cold pressor test (CPT). 
During the CPT, participants immersed their contralateral (left) hand up to the wrist in a 
circulating cold water bath maintained at 4°C, a water temperature used as conditioning 
stimulus in many previous CPM studies 12, 38, 64. Twenty seconds following hand 
immersion, PPT was reassessed on the right trapezius (i.e., the same site as baseline 
assessment). Participants were asked to remove their arm from the water 30 seconds 
after arm immersion. A second CPM trial was conducted two minutes after the end of 
the first CPM trial. The use of a 2-minute rest period between CPM trials is consistent 
with procedures that have been used in several previous CPM studies using the cold 
pressor test as the conditioning stimulus 30, 33, 38. Assessing CPM twice is also 
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consistent with recommendations on CPM testing. 85 For each of the CPM trials, a CPM 
index was derived by calculating the percent ratio of PPT during CPT to PPT prior to 
CPT. Scores from these two CPM trials were averaged, and higher CPM scores 
represented greater pain-inhibitory capacity.28, 31, 65, 85 
3.0. Data Reduction and Analysis 
 
All data were analyzed using IBM-SPSS v.21 (Chicago, IL, USA). The alpha level 
for significance was set to p < .05 for all analyses, and p-values above .05 are labeled in 
the Results section as NS (non-significant). Descriptive data for continuous variables 
were presented as means and standard deviations, and data for categorical variables 
were presented as percentages. Data for one of the CPM trials were missing for 7% of 
participants (i.e., 13/190). For these participants, data from the first CPM trial were used 
for the computation of the final CPM index. 
Prior to conducting the primary study analyses, the potential confounding 
influence of ethnicity, clinical pain intensity, pain interference, and pain duration on CPM 
and TS was examined. Variables associated either with CPM or TS were retained as 
covariates in subsequent analyses. 
A Pearson correlation was first computed to examine the association between 
CPM and TS. Pearson correlations were then computed to examine the association 
between psychological factors (i.e., catastrophizing, depressive symptoms) and 
endogenous pain modulation measures (i.e., CPM, TS), and independent samples t- 
tests were used to examine whether CPM and TS scores varied as a function of 
participant sex (i.e., men/women) and opioid status (i.e., opioid users/non-users). 
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In order to examine the potential moderating role of age, sex, opioid status, and 
psychological factors in the association between CPM and TS, five distinct moderation 
analyses were conducted using the PROCESS macro developed by Hayes et al. 43 For 
each of these moderation analyses, the TS index was used as the dependent variable, 
and two-way interaction terms between the CPM index and potential moderators (i.e., 
age, sex, opioid status, catastrophizing, depressive symptoms) were specified after 
inclusion of appropriate main effects. Any significant two-way interaction effect would 
suggest that the association between CPM and TS is moderated by participant age, 
sex, opioid status, catastrophizing, or depressive symptoms. Bias-corrected 95% 
confidence intervals (CI) were generated based on 5,000 bootstrap resamples, and CIs 
were presented along with p-values to interpret the significance of 
interaction/moderation effects. As recommended, moderation effects were considered 
significant in the case zero was not included within the CIs. Bootstrapping has been 
widely recommended because it improves power, but it was estimated that our sample 
size would be sufficient in order to detect medium-to-large effects using bootstrapping 
with two independent variables (IVs), an alpha set to .05, and a power of .80.43 
4.0. Results 
 
4.1. Descriptive statistics 
 
Descriptive statistics are presented in Table 1. In the present sample, 64 % (n = 
 
122) of participants were taking opioids (average daily opioid dose = 101.0 morphine 
equivalents; SD = 114.8). 
Prior to conducting primary analyses, the potential confounding influence of 
ethnicity, clinical pain intensity, pain interference, and pain duration on primary study 
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variables (i.e., CPM, TS) was examined. For opioid users, the influence of daily opioid 
dose on CPM and TS was also examined. None of these variables were significantly 
associated with either CPM or TS (see Table 2). Opioid users and non-users differed 
significantly on measures of clinical pain intensity (t (176) = -7.3, p < .01) and pain 
interference (t (154) = -8.4, p < .01), but not in pain duration. 
4.2. Association between psychological factors and endogenous pain modulation 
 
Table 2 also shows the correlations between psychological factors and 
endogenous pain modulation measures. Correlational analyses revealed a marginally 
significant negative association between catastrophizing and CPM (r = -.14, p = .05), 
indicating that higher levels of catastrophizing were associated with lower CPM. A 
significant positive correlation was found between catastrophizing and TS (r = .15, p < 
.05). Depressive symptoms were not significantly associated with either CPM or TS. 
 
Independent samples t-tests were used to examine whether CPM and TS scores 
varied as a function of participant sex (i.e., men/women) and opioid status (i.e., opioid 
users/non-users). Results indicated that there were no significant sex differences either 
in CPM (t (188) = 1.8, NS) or TS (t (188) = -.62, NS). Results of t-tests, however, 
indicated a marginally significant difference in CPM as a function of opioid status, with 
lower CPM scores for opioid users than non-users, t (188) = 2.1, p < .05. Opioid users 
and non-users did not differ significantly on the TS index, t (188) = -0.10, NS (see 
Figures 1 and 2). 
4.3. Association between CPM and TS 
 
A Pearson correlation was computed to examine the association between CPM 
and TS. Results revealed a significant negative correlation between CPM and TS 
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scores (r = -.20, p < .01), indicating that higher levels of CPM were associated with 
lower levels of temporal summation. 
4.4. Moderators of the association between CPM and TS 
 
As noted previously, five distinct bootstrapped moderation analyses were 
conducted to examine whether age, sex, opioid status, catastrophizing, or depressive 
symptoms moderated the association between CPM and TS. Results from these 
analyses indicated no significant 2-way interactions between CPM and participant age 
(B = .001, SE = .004, NS), sex (B = .053, SE = .099, NS), catastrophizing (B = -.006, SE 
= .004, NS), or depressive symptoms (B = -.001, SE = .006, NS). The two-way 
interaction effect between CPM and opioid status, however, was significant (B = .194, 
SE = .091, p < .05; LLCI = .014; ULCI = .375), indicating that the association between 
CPM and TS was moderated by participants’ opioid status. Simple slope analyses were 
subsequently conducted in order to probe the interaction of CPM and opioid status on 
TS. As can be seen from Figure 3, the association between CPM and TS varied as a 
function of participants’ opioid status (i.e., opioid users vs non-users). Results revealed 
a significant association between CPM and TS for non-users (r = -.34, p < .01), but not 
for opioid users (r = -.08, NS). 
5.0. Discussion 
 
Results of this study indicated that greater endogenous pain-inhibitory capacity is 
associated with lower levels of pain summation. Further, a moderation analysis revealed 
that the magnitude of this association differed significantly as a function of participants’ 
opioid status, with opioid use appearing to reduce the magnitude of the inverse 
relationship between CPM and TS. None of the demographic or psychologic variables 
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included in the present study were found to moderate the association between CPM 
and TS. 
The association that was found between CPM and TS is generally consistent 
with heuristic models of endogenous pain modulation that implicitly assume a certain 
degree of concordance between measures of pain inhibition and facilitation 4, 20, 27, 66, 84, 
86. For instance,  individuals  exhibiting either high  pain inhibition (high  CPM), low  pain 
 
summation (low TS), or both, have been collectively described as having an 
“antinociceptive” pain modulation phenotype, as opposed to a pro-nociceptive 
phenotype characterized by high TS and low CPM 40, 86. It is also noteworthy that 
individuals with chronic pain conditions characterized by “dysfunctional” pain modulation 
tend to show both decrements in CPM and elevations in TS relative to controls 1, 8, 22, 23, 
66. On the basis of this model, one would expect an inverse association between indices 
 
of endogenous pain inhibition and endogenous pain facilitation, which is what we 
observed in the present study. In addition, two recent studies found that roughly 30 % of 
individuals with “normal” or “higher-than-average” CPM levels were characterized by 
low levels of TS 56, 75, which is also consistent with our results. 
Interestingly, the present study found an association between measures of CPM 
and TS selectively among individuals who are not using opioids. While a number of 
factors might account for the altered association between CPM and TS among opioid 
users, our data suggest that this might be due at least in part to the potentially disruptive 
effects of exogenous opioids on individuals’ endogenous pain-inhibitory capacity. 
Consistent with previous work 29, 59, we found that the magnitude of CPM was lower for 
opioid users than non-users, suggesting that opioid use might dampen the functioning 
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of endogenous pain-inhibitory systems. Interestingly, several recent experimental 
studies have found that acute opioid administration may enhance endogenous pain 
inhibition 2, 53, and other reports of short-term administration have suggested minimal 
effects 73. Collectively, these findings may suggest that the impact of opioid use on 
indices of pain inhibition shows a biphasic time course, with acute potentiation of CPM 
followed by long-term decrements of CPM. There is now compelling evidence both from 
preclinical 15, 50 and clinical 77, 88 studies that opioid use, over time, may progressively 
lead to enduring neuroplastic changes at various levels of the central nervous system 
(CNS), including within neural pathways known to be involved in endogenous pain 
inhibition. To the extent that endogenous pain-inhibitory systems exert a modulatory 
influence upon pain summation 6, 25, 41, 81, opioid-induced disruption of pain-inhibitory 
function might compromise the expected association between pain inhibition and pain 
facilitation, as observed among opioid users included in the present study. Although 
speculative, a disruption of pain-inhibitory function as a result of repeated opioid use 
might contribute to enhanced descending facilitatory activity and, in turn, to opioid- 
induced hyperalgesia (OIH), a phenomenon observed both experimentally and clinically 
16, 17, 49, 72. The observational nature of our study design prevents from concluding that 
 
opioid use caused hyperalgesic responses (i.e., opioid-induced hyperalgesia). However, 
the significantly lower pain-inhibitory (i.e., CPM) function and heightened clinical pain 
intensity levels observed among opioid users compared to non-users provide partial 
support for this notion. Previous studies among individuals with chronic pain have also 
observed disruptions in CPM 28, 60, 90 and heightened clinical pain intensity levels 17, 18 
among long-term opioid users. However, given that these studies were also based on 
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observational study designs, research will be needed to determine whether a disruption 
of the association between pain-inhibitory and pain-facilitatory mechanisms may 
contribute to the development of opioid-induced hyperalgesia among individuals who 
initiate opioid therapy. 
The findings of the present study have not only implications for conceptual 
models of endogenous pain modulation, but also for the assessment of pain-modulatory 
profiles in treatment settings. For instance, the modest overlap (i.e., concordance) 
between measures CPM and TS suggests considerable inter-individual heterogeneity 
within each of the pain modulation profiles. Consequently, in clinic settings, these two 
measures should not be used interchangeably to derive inferences about individuals’ 
pain modulation. The predictive consideration of both CPM and TS paradigms is likely  
to yield a more reliable and comprehensive assessment of pain modulation profiles 55. 
Our findings also suggest that a certain “discordance” between measures of 
endogenous pain inhibition (i.e., CPM) and pain facilitation (i.e., TS) might be more 
particularly pronounced among specific subgroups of individuals with chronic pain, such 
as those using opioid medication. Given that the coupling of high pain inhibition and low 
pain facilitation is viewed as an optimal pain modulation profile (i.e., an “antinociceptive” 
PMP) with the potential for buffering against negative pain-related outcomes 25, 84, 86, the 
putative deleterious impact of opioids on individuals’ pain modulation profiles should be 
considered over the course of treatment selection, either in the context of perioperative 
or chronic pain management. Future research should also examine whether the 
association between pain inhibition and pain facilitation is enhanced when individuals 
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are discontinuing or tapering off opioid medication, as well as the time course of these 
putative shifts in pain modulation produced by changes in opioid treatments. 
A number of limitations must be considered when interpreting the present 
findings. First, this study report is based on a convenience sample, which limited our 
explanatory reach in accounting for some of the findings that were reported. Second, 
due to the cross-sectional nature of the study design, individuals’ levels of CPM and TS 
were assessed only at a single point in time. While these two measures have been 
found to be relatively stable over time 11, 14, 42, 44, 52, future studies involving repeated 
assessment of CPM and TS would allow one to derive more reliable inferences about 
the magnitude of the association between these two forms of endogenous pain 
modulation. Third, participants in the present study were taking relatively high doses of 
opioids considering recent changes in opioid prescribing guidelines 24. Daily opioid 
doses were neither associated with CPM nor TS, but further studies will need to 
determine whether our findings can be generalized to patients taking lower opioid 
doses. It will also be important to further evaluate the influence of opioid dose and 
opioid use duration to the functioning of endogenous pain modulation systems. Fourth, 
individuals taking non-opioid analgesic medications were not included in the analyses. 
While this may be seen as a methodological strength, as it permitted us to rule out the 
influence of non-opioid medication on endogenous pain modulation, this places limits on 
the generalizability of our findings. Fifth, we did not measure potentially important 
variables, such as the duration of opioid therapy or the recency of opioid use in relation 
to QST. Future studies should control for inter-individual differences in these variables 
as they might influence measures of pain modulation. Finally, CPM was derived only on 
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the basis of the cold pressor test and pressure pain stimuli. Replication of our findings 
using other methods or CPM paradigms (i.e., using other conditioning and/or test 
stimuli) 44 is warranted before drawing more firm conclusions regarding the association 
between CPM and TS. 
Conclusion 
 
Findings from the present study provide new insights into the association 
between endogenous pain-inhibitory and pain summation systems, showing an inverse 
relationship between CPM and TS among individuals with chronic pain. That is, those 
exhibiting higher levels of CPM showed lower levels of TS. While the coupling of high 
pain inhibition and low pain facilitation is viewed as an optimal endogenous pain 
modulation profile that may buffer against negative pain-related outcomes 25, 84, the 
present findings suggest that opioid use might disrupt endogenous pain-inhibitory 
function and, in turn, the association between endogenous pain-inhibitory (i.e., CPM) 
and pain-facilitatory (TS) systems. Given that an impaired association between pain- 
inhibitory and pain-facilitatory systems is expected to increase individuals’ vulnerability 
to poor pain-related outcomes 25, 56, 84, further research will be needed to identify the 
factors that may impair the interrelationship between these endogenous pain 
modulatory systems. Research will also be needed to determine whether a disruption of 
the association between pain-inhibitory and pain-facilitatory mechanisms may contribute 
to long-term sensitization and hyperalgesic responses (i.e., opioid-induced 
hyperalgesia) among opioid users. Research in this area would provide additional 
insights into the potentially deleterious impact of opioids on endogenous pain 
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modulation systems, and would have implications for the management of individuals 
with pain conditions. 
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Sample characteristics and descriptive data for main study variables 
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Correlations among study measures 
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Figure 1 
Conditioned pain modulation scores for opioid users and non-users 
 
Figure 2 
Temporal summation of pain scores for opioid users and non-users 
 
Figure 3 
Association between conditioned pain modulation and temporal summation as a 
function of individuals’ opioid status 
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